Mesenchymal stromal cells and rheumatic disorders

Area of Science:

• Immunology
• Regenerative Medicine
• Rheumatology

Background:

• Mesenchymal stromal cells (MSC) are extensively studied for rheumatic diseases.
• Despite promising preclinical data, clinical benefits remain largely unproven.
• Potential reasons for this discrepancy include terminology, study design, and outcome measures.

Purpose of the Study:

• To review the clinical efficacy of MSC in rheumatic diseases.
• To discuss the challenges hindering successful MSC translation to the clinic.
• To explore reasons for the gap between preclinical expectations and clinical reality.

Main Methods:

• Review of published randomized controlled trials and uncontrolled studies.
• Focus on systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and osteoarthritis (OA).
• Analysis of studies involving MSC in conjunction with standard care or surgical interventions.

Main Results:

• Limited positive outcomes in randomized controlled trials for rheumatic diseases.
• Some positive results reported for SLE and RA from single centers.
• Mixed evidence for osteoarthritis, with some benefit noted in combination with surgery.

Conclusions:

• MSC efficacy in rheumatic diseases requires further investigation.
• Standardization of MSC terminology and clinical trial design is crucial.
• The current application of MSC may not be effective, necessitating a re-evaluation of therapeutic approaches.